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LEONARD v.B. SUTTON AWARD
PAPER
Human Rights and Access to Health Care:
Comparison of Domestic and International
Law and Systems Implications for New
Medical Technologies in Time of Crisis
I. INTRODUCTION
Three years prior to the American Civil War, Abraham Lincoln
stated that "a house divided against itself cannot stand.", With the ad-
vent of international telecommunications, extensive travel and economic
interdependence, the world is shrinking. As witnessed by the AIDS epi-
demic2 and various strains of influenza,3 localized health problems in
third world countries quickly find their way into one's own back yard.4
Traditional methods for differentiating domestic and international health
problems have lost their meaning.5 With regard to what is currently
known about past and present health crises, the "global village" has be-
come a global house.
This house is extremely divided. The divisions begin with basic dif-
ferences in the way in which societies perceive human rights in general.
Differing philosophies lead to different systems.' When applied to health
care, present systems leave much to be desired.
The aim of this paper is to examine these differences from the per-
spectives of history, treaties and law. Once these differences have been
1. Abraham Lincoln, speech at the Republican State Convention, Springfield Illinois
(June 16, 1858). Lincoln borrowed this phrase from the New Testament of the Bible, Mat-
thew 12:25, Luke 11:17.
2. Dr. Jonathan Mann, Global AIDS into the 1990's, WORLD HEALTH, Oct. 1989, at 6.
3. CHARLES STUART-HARRIS, INFLUENZA, THE VIRUSES AND THE DISEASE 124-31 (2d ed.
1985).
4. Id.
5. George A. Gellert, The Obsolescence of Distinct Domestic and International Health
Sectors, 10 J. PUB. HEALTH POL'Y 421-22 (1989).
6. Louis Henkin, Rights: Here and There, 81 COLUM. L. REv. 1582, 1609 (1981).
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surveyed, they are analyzed in situations where their different systems
must work together. Their probable effects are examined in a potential
international crisis with regard to application of an incredible array of
new medical technologies. Obstructions to their use in a crisis are then
explored based on present law and actual experience. Conclusions and
recommendations flow directly from that analysis.
II. DIFFERING VIEWS ON BASIC HUMAN RIGHTS
The main philosophical difference in human rights perception has
been described as that between "freedom from," aspiring to individual
autonomy, and "having more," through more law and government.7 These
differences have also been termed "political" rights and "socio-economic"
rights. The political rights are immunities or rights against invasion by
the government. The socio-economic rights are rights to affirmative aid
and support by one's government.8
"You owe me nothing; I owe you nothing. You stay out of my way
and I'll stay out of yours." This expression has been described as consti-
tuting an important thread within the Anglo-American socio-moral
fabric.9 The American theory of rights is derived from individual freedom
and autonomy, not claims upon society to do for the individual what he
can not do for himself. The framers of the U.S. Constitution, perhaps due
to their difficulties with Great Britain, saw rights as freedom from abuse
by all branches of government.'0
In the United States, programs regarding public welfare do not exist
by constitutional mandate, but by the grace of Congress, subject to politi-
cal and budgetary constraints." There is no constitutional right to free-
dom from want."s Where some responsibility for individual welfare was
finally recognized, it was seen as secondary and supplementary."
Public welfare statutes are considered "entitlements" instead of
rights.'" U.S. courts have reviewed such entitlements based on the "equal
protection" clause of the Fourteenth Amendment to the U.S. Constitu-
tion.15 Their standard for review is whether or not "similarly circum-
7. Id.
8. Levy, Making Human Rights More Definite and Effective, in HUMAN DIGNITY, THE
INTERNATIONALIZATION OF HUMAN RIGHTS 249 (A. Henkin ed. 1979).
9. SANFORD H. KADISH AND STEPHEN J. SCHULHOFER, CRIMINAL LAW AND ITS PROCESSES
206 (5th ed. 1989).
10. Henkin, supra note 6, at 1592.
11. Id. at 1587.
12. Id.
13. Id. at 1590.
14. Elliot v. Ehrlich, 280 N.W.2d 637, 641 (1979); Goldberg v. Kelly, 397 U.S. 254, 262
(1970).
15. Wendy K. Mariner, Access to Health Care and Equal Protection of the Law: The
Need for a New Heightened Scrutiny, 12 AM. J. L. & MED., 345, 347 (1986). The Fourteenth
Amendment states, "No State shall... deny to any person within its jurisdiction the equal
protection of the laws." U.S. CONST. amend. XIV, cl. 1.
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stanced" individuals are treated by the government in a similar manner.8
Consequently, the courts will review whether or not one segment of the
poor is treated by the government differently from another segment of
the poor. They will not decide whether the poor are being treated differ-
ently from the wealthy.1 7 It does not guarantee equal treatment for all.' s
Within the U.S. several states have found that their own constitutions
provide greater protection than the Fourteenth Amendment. 9
The United States has ratified fewer human rights treaties than the
vast majority of countries.2 0 The U.S. is not a party to the International
Covenants on Human Rights."' Some authors believe that treaty ratifica-
tion would have little impact on American human rights because the "rel-
evant domestic law in many respects already ensures more rights than its
international counterpart.
2
In contrast, the French concept of freedom is not freedom from the
law, but through the law.2 1 It includes the economic and social benefits of
the welfare state as affirmative obligations of government. 2 When com-
paring their respective declarations of rights, due to their different histor-
ical backgrounds, the Americans declared what they had and the French
declared what they desired.
25
The French concept is in accordance with most international agree-
ments on human rights. The Universal Declaration of Human Rights in-
cludes the right to have basic human needs satisfied - food and shelter,
health care, and education.2 The International Covenant of Economic,
Social and Cultural Rights contains similar provisions. 27 The European
Declaration of Fundamental Rights and Freedoms contains identical con-
cepts providing for collective social rights, social welfare and the right to
education. 28
The Council of Europe under the European Convention on Human
16. Id. at 349.
17. Id. at 353-54. See also Shapiro v. Thompson, 394 U.S. 618, 641 (1969) (rejecting
state residency requirements for welfare recipients as a denial of due process for poor
travelers).
18. Mariner, supra note 15, at 349.
19. Id. at 377.
20. Thomas Buergenthal, The U.S. and International Human Rights, 9 Hum. RTS. L.J.
141 (1988).
21. Id. at 142.
22. Buergenthal, supra note 20, at 161.
23. Henkin, supra note 6, at 1597.
24. Id.
25. Id. at 1592.
26. Universal Declaration of Human Rights, arts. 25 and 26, G.A. Res. 217, U.N. Doc.
A/810 (1948) [hereinafter G.A. Res. 217].
27. The International Covenant on Economic, Social and Cultural Rights, G.A. Res.
2200 (annex), 21 U.N. GAOR, Supp. (No. 16) at 49, U.N. Doc. A/6316 (1967).
28. The European Parliament Declaration of Fundamental Rights and Freedoms of 12
April 1989, reprinted in 10 Hum. RTS. L. J. 341 (1989) [hereinafter European Parliament
Declaration].
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Rights established a Commission and Court of Human Rights which
hears cases by both governments and individuals.2" In 1975 there were
approximately 2,000 cases brought before the European Commission of
Human Rights. In 1987, the number had grown to 3,675.30 About one-fifth
of these lead to applications that are decided by the Commission."1 The
compliance rate by defendant governments is thought to be unusually
high. " Finland became the twenty third Member State of the Council of
Europe on May 5, 1989 and signed the European Convention on Human
Rights."3
III. U.S. LAW REGARDING ACCESS TO HEALTH CARE AND ITS EFFECTS
There is no duty within the United States Constitution or statutes to
provide medical care for the indigent.3 4 The duty to provide indigent care
is most often found in state statutes.3 ' Nearly every state has a statutory
provision which authorizes or mandates state or local governments to pro-
vide medical care for the poor." Fifteen states have constitutional provi-
sions providing for such care. 7 Laws for the benefit of the public welfare
are generally construed liberally due to their remedial purpose, conse-
quently courts tend to favor mandatory interpretation unless a statute is
clearly permissive.3 " Where permissive', rather than mandatory, courts
will not compel governments to provide medical assistance.3 9
In recent years, state and local indigent care budgets have been
strained due to tax revenue declines, rising health care costs and changes
in federal reimbursement programs.' Thirty-seven million patients have
no health insurance.' The number of persons who lack health insurance
has increased by 34.7% from 1977 to 1983."' AIDS patients now fill 9% of
all hospital beds in New York City. It is estimated that 2,300 additional
29. Levy, supra note 8, at 20.
30. Henry G. Schermers, Has the European Commission of Human Rights Got Bogged
Down?, 9 HuM. RTS. L.J. 175 (1988).
31. Id.
32. Levy, supra note 8, at 20.
33. Announcement: Council of Europe Strausbourg, Finland Joins the Council of Eu-
rope and Signs the European Human Rights Convention, 10 HUM. RTS. L.J. 355 (1989).
34. See Wideman v. Shallowford Community Hospital, 826 F.2d 1030, 1032 (11th Cir.
1987).
35. M. Dowell, State and Local Government Legal Responsibilities to Provide Medical
Care for the Poor, 3 J. HEALTH L. 1, 3 (1988-89).
36. Id. at 4.
37. Id. at 6.
38. Id. See also Damon v. Secretary of HEW, 557 F.2d 31, 33 (2d Cir. 1977).
39. Dowell, supra note 35, at 4 n. 29; see also Perth Amboy Gen. Hosp. v. Board of
Chosen Freeholders, 386 A.2d 900 (N.J. Super. Ct. 1978).
40. Id. at 2.
41. Nancy Gibbs, Emergency, TIME, May 28, 1990, at 59.
42. See Dowell, supra note 35, quoting Robert Wood Johnson Foundation, Updated
Report on Access to Health Care for the American People, Special Report No. 1 (1983).
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beds will be needed in New York for the treatment of AIDS alone. 4 Gov-
ernment reimbursements often cover only half of the cost of treating the
poor." In emergency rooms the typical trauma patient bill in 1989 was
$13,000; on average, hospitals take a loss of $5,000 on each.45
"Research indicates that if life support is used on serious heart at-
tack victims within four minutes, and advanced life support within eight,
nearly 50 percent of them survive."' 6 Peoria, Illinois, saw traffic fatalities
drop 50 percent within a year of setting up their trauma network.47
Deaths among non-head-injured car accident victims dropped from an es-
timated 73 percent to 9 percent in Orange County, California.48 Despite
these remarkable advances in techniques and equipment, according to the
National Association of Hospital Development, 40% of the nation's acute
care hospitals will be closed by the year 2000.' Four of ten trauma cen-
ters in the City of Chicago have closed. Every hospital except one in Dade
County, Florida, has closed its trauma department. That remaining hos-
pital must service a population of two million residents.5" "The hospitals
don't just close their doors to poor people, when they're closed, they're
closed to everyone. '' 1
IV. EUROPEAN LAWS, INTERNATIONAL COVENANTS AND HEALTH CARE
The goal of equal access to health care is stated in a wide variety of
international documents. The World Health Organization (WHO) was the
first body to recognize the right to health as one of the fundamental
rights possessed by every human being.52 The World Health Assembly of
WHO adopted the "Health for All" resolution in 1977 stating that "the
main social target of WHO in the coming decades should be the attain-
ment by all citizens of the world, by the year 2000, of a level of health
that will permit them to lead a socially and economically productive
life."5" Article 12 of the International Covenant on Economic, Social and
Cultural Rights54 recognizes the right to the "highest attainable standard
of physical and mental health," including "the creation of conditions
which would assure to all medical service and medical attention in the
event of sickness." Article 25 of the Universal Declaration of Human
43. Gibbs, supra note 41, at 65.
44. Id. at 59.
45. Id. at 63.
46. Id. at 59.
47. Id. at 63.
48. Id.
49. Id. at 64.
50. Id. at 59.
51. Id., quoting Virginia Price-Hastings, Director of Los Angeles Trauma Hospital
Programs.
52. Genevieve Pinet, The WHO European Program of Health Legislation and Health
for All Policy, 12 AM. J.L. & MED. 441, 443 (1986).
53. World Health Assembly Resolution WHA 30.43 (1977).
54. See G.A. Res. 2200, supra note 27.
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Rights 8 proclaims that everyone has the right to a standard of living ade-
quate to sustain health, including medical care and necessary social ser-
vices. Although not accorded the status of an international treaty,56 the
Helsinki Accords seek to bind signatories to the provisions of both the
Universal Declaration of Human Rights and the International Covenant
on Economic, Social and Cultural Rights." Article 15(3) of the European
Declaration of Fundamental Rights and Freedoms5 8 declares that anyone
lacking sufficient resources shall have the right to social and medical
assistance.
Great Britain and Canada have had nationalized health care for an
extended period of time. 9 Several West European nations have followed
the principals of the international accords by enacting either socialized
medicine or proactive legislation that increases the role of government in
the provision of equal access to health services. Included among these na-
tions are Finland, Italy, Greece, the Netherlands, Sweden, Iceland, Nor-
way, Spain and Belgium.6 0
Recent statistics have indicated that "[e]quity in access to medical
care has clearly failed to assure equity in health."61 For instance, the in-
equity in mortality of social classes has widened since the implementation
of the National Health Service in Great Britain.6 2 The standard mortality
ratio for semiskilled and unskilled workers has steadily increased from
1951 to 1971.63 This indicates that proportionately far fewer semiskilled
and unskilled laborers survive long enough to meet the average life expec-
tancy. The difference between the mortality rates of these lower classes
and those of the upper social classes (professional and managerial) has
also grown substantially."" Scotland is now the nation with the highest
death rate from coronary heart disease. Finland, England and Wales are
not far behind.65
A similar pattern has developed in Canada. The difference in life ex-
pectancy between lowest and highest income levels was 4.5 years in the
late 1970's. The difference was eleven years for disability-free life expec-
tancy. "Poor people in Canada have, on the average, only 55 years of
55. See G.A. Res. 217, supra note 26.
56. HUMAN RIGHTS, PROBLEMS, PERSPECTIVES AND TEXTS 197 (F.E. Dowrick ed., 1979).
57. Conference on Security and Cooperation in Europe: Final Act, Helsinki 1975, re-
printed in HUMAN DIGNITY, THE INTERNATIONALIZATION OF HUMAN RIGHTS 135, 140 (Alice H.
Henkin ed. 1979) [hereinafter Helsinki].
58. See European Parliament Declaration, supra note 28, at 344.
59. Editorial, How Important is Medical Care in a National Health Program, 9 J. PUB.
HEALTH POL'Y 7, 7-8 (1988) [hereinafter How Important].
60. Pinet, supra note 52, at 447-48.
61. Editorial, Ethical Essentials of a National Health Care Program, 11 J. PUB.
HEALTH POL'Y 5, 5 (1990) [hereinafter Ethical Essentials].
62. Id.
63. How Important, supra note 59, at 8.
64. Id. at 9.
65. Id. at 8.
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healthy life, that is, life free from disability, as compared with 66 years of
healthy life for rich Canadians."'6 6 During the 1970's Canada's death rate
from lung cancer rose by 60 percent and death from cirrhosis of the liver
by 25 percent.
6 7
Various reasons have been offered to explain these differences, in-
cluding unstable economies resulting in high unemployment.8 Socialized
medical systems have been strongly criticized for being overly bureau-
cratic, budget-oriented, and for only allowing support for the short-term
needs of its users, while neglecting new techniques and medical innova-
tion.6 9 The lack of emphasis on preventive medicine is frequently cited as
the biggest problem. It has been contended that "[e]quity in prevention is
more important than equity in medical care. "70
V. POTENTIAL INTERNATIONAL CRISIS - THE SPREAD OF RAPIDLY
CHANGING VIRUSES, THEIR EFFECTS AND PREVENTION
Both capitalist and socialist health care systems have logistic and fi-
nancial problems. Health complications experienced in one nation can
rapidly cross borders and become worldwide complications. The changing
nature of the AIDS virus and of influenza, coupled with the diminished
effectiveness of vaccines, illustrates the probability of new worldwide
problems that these disparate systems may have to address. This section
deals with the nature of these new challenges, prior to analyzing ways to
meet them and the laws that may prevent them from being met.
The WHO Global Programme on AIDs estimates that about one-
tenth of one percent of the world's population is infected with the human
immunodeficiency virus (HIV). About half of these people are in Africa,
forty percent are in the Americas, and the remainder are scattered
throughout the rest of the world.71 It is projected that at least seventy-
five percent of those infected will develop AIDS within twenty years."s
The lifetime medical costs for a single AIDS patient is estimated to be
approximately $150,000. At present, life expectancy for a newly diagnosed
AIDS patient averages about one year.73 For 210,000 additional cases, the
cost would exceed thirty billion dollars.7 4 A variety of nations, including
the United States, have enacted legislation designed to restrict the immi-
66. Id. at 9.
67. Id. at 8.
68. Id.
69. Note, Socialized Medicine: An Analysis of Bureaucratic Inefficiency, 8 DICK. J.
INT'L L. 101, 121 (1989).
70. How Important, supra note 59, at 9.
71. Dr. Jonathan Mann, Global AIDS into the 1990's, WORLD HEALTH, October 1989, at
6.
72. Dr. J. Chin, Understanding the Figures, WORLD HEALTH, October 1989, at 9.
73. Balaji B. Singh et al., The Impact of AIDS on Medical Disposables, 11 MED. DE-
VICE AND DIAGNOSTIC INDUSTRY 61, 61, September 1989.
74. Id.
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gration of those who might have AIDS."
While the effects of AIDS and its methods of transmission have been
publicized extensively, other facts about the virus have not received the
same degree of exposure. For example, the rate of genetic change for por-
tions of the AIDS virus has been found to be over a million times greater
than that of most normal (eukaryotic)71 cells.7 The AIDS virus is capable
of mutating in several different wayss7 8 including the sharing of genetic
material between different HTLV molecules.79 More than one predomi-
nant viral form has been persistently found within the same individual.8 0
A wider range of cellular types may be infected by HIV than was previ-
ously thought."1 Given the extensive variation in the genes of the AIDS
virus, it "clearly has the potential for drastically altering both its immu-
nologic and biologic properties." '2 The AIDS virus of today, including its
methods of transmission, may not be the AIDS virus of tomorrow.
The only other virus that approaches the rate of mutation of AIDS is
Influenza Type A.8" Although their modes of transmission and lethality
are currently different, Type A flu was studied extensively, and it is a
good example of the worldwide effect that an .organism can have in a
short period of time. In February of 1957, Type A influenza appeared in
China.8 4 By April, it had spread to Hong Kong and throughout Southeast
Asia; by May, it had spread to India and Australia."0 From that point, it
took only three more months to spread over the rest of the earth." In the
United States, Type A flu caused an estimated 70,000 excess deaths, with
health care and productivity losses of four billion dollars.8 7 In 1968, a
milder reoccurrence of the virus is estimated to have cost 34,000 lives and
two to three billion dollars.88
In 1977, the virus again reappeared, taking approximately eight
75. Note, The AIDS Pandemic: International Travel and Immigration Restrictions
and the World Health Organization Response, 28 VA. J. INT'L L. 1043, 1052-55 (1988).
76. Eukaryotic cells are those with a nucleus; prokaryotic cells do not have a normal
nucleus. MEDICAL TECHNOLOGY, BOARD EXAMINATION REVIEW, Vol. 1, at 397, 8th ed. (Edith
Zak Helman et al. eds. 1975).
77. Bruno R. Starcich et al., Identification and Characterization of Conserved and Va-
riable Regions in the Envelope Gene of HTLV-III/LAV, the Retrovirus of AIDS, 45 CELL
637, 643 (1986).
78. Starcich, supra note 77, at 643.
79. Id. at 645.
80. Id.
81. Robin A. Weiss and Jay A. Levy, Virology Overview, 2 AIDS S, S2 (Supp. 1, 1988).
82. Starcich, supra note 77, at 646.
83. Id. at 643.
84. ARTHUR M. SILVERSTEIN, PURE POLITICS AND IMPURE SCIENCE, THE SWINE FLU AF-
FAIR 14 (1981).
85. Id. at 14-15.
86. Id. at 15.
87. Id. at 19.
88. Id.
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months to cover the earth. 89 During this outbreak, an additional strain of
the virus was isolated. The two versions occurred simultaneously in single
localized areas. 90 The infection rates in children of Great Britain varied
from twenty to eighty percent.9"
Vaccines developed to fight these viruses have limited effectiveness.
Despite many trials, and the use of vaccines for many years, the degree of
protection for rapidly changing viruses remains in doubt.92 One study es-
timates vaccine effectiveness to be only forty to sixty-six percent. 93 An-
other indicates only fifty to sixty-seven percent effectiveness.94
The World Health Organization has recognized that there are many
infectious diseases for which vaccines are not yet available or are not sat-
isfactory.95 Effective vaccines have been developed against smallpox, yel-
low fever, polio, measles, mumps, German measles and others. 96 While
immunization against rapidly changing viruses is still important, "no
short-term experience is a reliable guide to the future pending develop-
ment of other measures such as chemotherapy."9 7
VI. POTENTIAL SOLUTIONS
Given the potential for such rapidly breaking health problems, possi-
ble solutions should be reviewed prior to analyzing international legal re-
strictions that could prevent the use of these new remedies in a crisis.
Two promising concepts are presented. The first is genetically engineered
drugs, and the second is computerized medical devices.
A. Biotechnology and Genetically Engineered Drugs
In 1973, Paul Berg of Stanford University used a series of specialized
enzymes to remove a piece of genetic material from a monkey virus. A
similar process was used to open the DNA in another strain of virus. He
then linked the genetic material from the first virus with that of the sec-
ond. He was the first to succeed in combining the genetic code in two
different organisms. In 1980, he was awarded the Nobel prize in chemis-
try for his efforts.9"
Dr. Berg had founded the science of recombinant DNA. Recombinant
DNA technology makes it possible to change the genetic instructions of a
living cell, in order to produce desirable proteins and other large mole-
89. STUART-HARRIS, supra note 3, at 131.
90. Id. at 130.
91. Id.
92. Id. at 192.
93. Id. at 192, 198.
94. Id. at 193.
95. New and Activities, 66 BULL. WORLD HEALTH ORGANIZATION 515, 519 (1988).
96. SILVERSTEIN, supra note 84, at 9.
97. STUART-HARRIS, supra note 3, at 182.
98. THE ALMANAC OF SCIENCE & TECHNOLOGY, 89 (R. Goleb ed. 1990) [hereinafter
ALMANAC].
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cules in large quantities. These changes are inherited by each succeeding
generation of the cell.99
In the case of Diamond v. Chakrabarty, the United States Supreme
Court held that a human made living organism is patentable, as a new
and useful manufacture or composition of matter.10 0 More than one hun-
dred potential products for human use were estimated to be under devel-
opment by biotechnology companies in 1987.101 Sales of health care prod-
ucts derived through biotechnology were expected to approach 900
million dollars in 1988.102 Over two billion dollars had been invested by
1984,010 and 700 U.S. companies were using the technology by 1988.'04
This technology is adaptable to a wide variety of uses. An excellent
example is found in medication used to treat heart attacks. Approxi-
mately 4,000 people have a heart attack each day.105 Chances of survival
largely depend on how much permanent muscle damage the heart sus-
tained during the time a clot blocked the normal flow of blood into the
heart (myocardial infarction). 10 6 Tissue plasminogen activator (tPA), an
enzyme which is naturally present in uterine tissue, dissolves blood clots.
It is now being produced, by Genentec Inc., through genetically altered
bacteria. 10 7
In a European study, patients treated with the drug experienced
mortality reductions of 51% at fourteen days when compared to a control
group, and 36% at three months. When tPA was administered within
three hours of heart attack symptoms, mortality was reduced by 82% at
fourteen days post attack, and 59% at three months.10 8 "Activase" (tPA)
was approved by the FDA in November of 1987.109
Many believe that it will be the world's second billion dollar drug.1 0
One dose costs about $2,200, compared to $200 to $300 for another drug,
Streptokinase. Streptokinase also dissolves blood clots but is somewhat
less effective than tPA.111 Sales of tPA were estimated to be 180 million
99. Michael Traynor, Emerging Product Liability Issues in Biotechnology, 3 HIGH
TECH. L.J. 149, 159 (1988).
100. Diamond v. Chakrabarty, 447 U.S. 303 (1980); see also 35 U.S.C. § 101 (1982).
101. ALMANAC, supra note 98, at 98, quoting U.S. Cong. Off. Tech., New Developments
in Biotechnology (1987).
102. Id., quoting Consulting Resources Corp. of Lexington, Mass.
103. Marciniszyn, What Has Happened Since Chakrabarty? 2 J. L. & HEALTH 141, 141
(1987-88), quoting Biotech Comes of Age, Bus. WK., Jan. 23, 1984, at 84-85.
104. Id. at 141.
105. Editorial, The TPA Decision, WALL ST. J., May 28, 1987, at 30, col. 1.
106. Id.
107. ALMANAC, supra note 98, at 99.
108. Frans Van de Werf, Lessons from the European Cooperative Recombinant Tis-
sue-Type Plasminogen Activator (rt-PA) Verses Placebo Trial, 12 J. AM. C. CARDIOLOGY
14a (Supp. 1988).
109. ALMANAC, supra note 98, at 98.
110. Marciniszyn, supra note 103, at 153.
111. Eric J. Topol, Tissue Plasminogen Activator: Why the Backlash?, 13 J. AM. C.
CARDIOLOGY, 1477 (1989).
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dollars in 1988. 12
Another example of recombinant DNA technique is Erythropoietin
(EPO). This is a human hormone that stimulates bone marrow cells to
grow into red blood cells. Kidney failure reduces production of EPO to
the extent that twenty-five percent of the 250,000 individuals worldwide
who require dialysis of their blood, also require frequent blood transfu-
sions. Using recombinant DNA techniques, EPO is now manufactured by
cultured mammalian cells." s
In clinical trials using EPO, virtually all severely anemic patients
were transfusion independent at the end of two months." 4 The market
for EPO is likely to go well beyond kidney patients to other anemic pa-
tients in need of increased red blood cell production,'1 5 including AIDS
and cancer patients." 6 The FDA released EPO for sale in June of 1989.1"
Interferons, proteins that the body produces in small quantities in
response to viral infections, provides a third example of this technique.
They stimulate infected cells to manufacture substances that prevent vi-
ruses from reproducing. They also stimulate some cancer cells to make a
type of protein that increases the chances that these cancer cells will be
recognized and eliminated by the immune system. Genetic material for
the production of interferons has now been spliced into two species of
bacteria and one species of mold.118 The FDA approved one type of in-
terferon for treatment of a specific type of cancer (hairy-cell leukemia) in
June of 1986."' Clinical evaluations have been underway for the use of
interferons in the treatment of several other types of cancer, influenza
and the common cold. 20
Other important developments in genetically engineered products in-
clude Human Growth Hormone for the treatment of dwarfism; In-
terleukins which stimulate the immune system and are currently used in
the treatment of kidney cancer; Factor VIII, one of the enzymes that
hemophiliacs lack rendering their blood unable to form clots; and Tumor
Necrosis Factor, which attacks tumors directly. More than eighty other
drugs produced by genetic engineering were being tested in humans at
the end of 1988.121
112. ALMANAC, supra note 98, at 99.
113. Id. at 105.
114. Epoetin Alfa Approved for Anemia Treatment, 262 JAMA 184 (July 14, 1989).
115. Anderson, Growing Pains for Amgen as Epoetin Wins U.S. Approval, 339 NATURE
493 (June 15, 1989).
116. Id.
117. ALMANAC, supra note 98, at 99.
118. Id.
119. Marciniszyn, supra note 103, at 151.
120. Id. at 151.
121. ALMANAC, supra note 98, at 105.
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B. Multiple-Use Computerized Medical Devices
Tremendous strides have also been made with electronic medical
equipment. Automated Centrifugal Blood Cell Separators effectively sep-
arate whole blood into three basic components: erythrocytes (red blood
cells), plasma and buffy coat (platelets and white blood cells). '22 Although
initially designed to collect and transfuse large numbers of platelets and
white blood cells, ' the advantages of being able to rapidly and accu-
rately remove specific elements from the blood were soon realized.
In an experiment involving two patients with drug resistant bronchial
asthma, for example, 40% to 80% of existing plasma protein was removed
from the blood stream. This fraction of the blood contains circulating im-
munocomplexes, auto-antibodies, toxins and metabolic products. Follow-
ing treatment with this procedure, the first patient had no attacks over a
period of five months. The other patient had no attacks for over a year.
Prior treatment with drugs was ineffective. 24
In 1984, the American Society of Apheresis appointed a committee to
review existing experience with the technology, and develop position pa-
pers based on the best available information. 125 A listing of over fifty pre-
sent and potential applications was presented. Included in that list was
mysathemia gravis, rheumatoid arthritis, sickle cell disease, lupus, Guil-
lain-Barre' syndrome, drug overdose and poisoning, hairy-cell leukemia,
multiple sclerosis, burns, asthma, AIDS and solid tumors.' 26 Since the
compilation of that data, this equipment has also been used in the treat-
ment of leprosy.'2 7
VII. FACTORS INHIBITING THE USE OF NEW MEDICAL TECHNOLOGIES
DURING AN INTERNATIONAL CRISIS
As remarkable as these new technologies in medicine may be, obsta-
cles to their use in an international crisis are formidable. A basic compre-
hension of methods used to test new medical products for safety is
needed to perceive the factors that may prevent their use in an interna-
tional emergency. In the United States, "adequate and well controlled"
studies, including human clinical investigations, are required for the pres-
entation of the substantial evidence needed for approval of a new medical
product. Effectiveness of a drug should normally be supported by more
than one well controlled trial and carried out by independent investiga-
122. Introduction, 1 J. CLINICAL APHERESIS 119 (1983).
123. Id.
124. Bamburger, Drug-Resistant Bronchial Asthma Successfully Treated with Plasma
Exchange, 2 J. CLINICAL APHERESIS 200, 200-205 (1984).
125. Introduction, 3 J. CLINICAL APHERESIS V (1986).
126. Id. at vi.
127. D. Wallach, Plasma Exchange in Severe Erythema Nodosum Leprosum, 9 INT'L J.
ARTIFICIAL ORGANS 183 (1986).
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tors.3 8 They generally require the administration of a placebo, a neutral
preparation given as a medicine, as a control for comparison. 129 In some
cases, this requirement may be abandoned for an "historical control
where a disease has a high and predictable mortality."13 0
Data from all animal studies are required to be reported, particularly
animal tests for cancer and birth defects (carcinogenicity and teratogenic-
ity). 31 Specific analysis of numerous drug interactions must be reported
using human test subjects. These effects are checked for differences with
sex, race, age and size, and might include such factors as disease severity,
concomitant illness, concomitant drugs, smoking and ethanol usage his-
tory and prior therapy.1 3 2 In order to support the safety and effectiveness
of each claim for the drug, each important segment of this analysis must
be "statistically" significant, according to a number of methods."'3
Biological factors for each test patient are studied. These include
items such as drug absorption, distribution within the body, metabolism
and excretion."" Dose range and dose response studies include such items
as the effects of the drug on heart rate, with exercise, at different dosage
levels. Other studies include effects on blood flow, kidney function, diges-
tive system motility, gastric acid secretion, the immune system, nervous
system, coagulation 3 5 and liver function.3 6
The aim of thoroughness is to attempt to identify all potential ad-
verse reactions to the product. Even with the best of studies, however,
this is impossible.137 Clinical testing using up to 500 patients can be ex-
pected to turn up adverse reactions that affect ten percent or more of the
population but may miss a less frequent danger. Delayed effects, unusual
toxic reactions and unpredictable effects due to genetic variables are diffi-
cult to detect.3 8s
A good example of the problem posed by human genetic diversity is
the essential enzyme glucose-6-phosphate dehydrogenase (G6PD) in red
blood cells. Over 370 genetic variants of this enzyme have been discov-
ered. ' 9 About forty variants are associated with a mild deficiency, but
128. U.S. Dept. Health Hum. Services, Public Health Service Food and Drug Admin.,
Guideline for the Format and Content of the Clinical Sections of New Drug Applications,
15 (July 1988) [hereinafter Guideline].
129. 21 C.F.R. § 314.126(b)(2)(i) (1989).
130. 21 C.F.R. § 314.126(b)(2)(v) (1989).
131. Guideline, supra note 128, at 42.
132. Id. at 32.
133. Id. at 69.
134. Id. at 12.
135. Id. at 12-13.
136. Id. at 33.
137. D. KAY, THE INTERNATIONAL REGULATION OF PHARMACEUTICAL DRUGS 48 (West
1976).
138. Id.
139. Beutler, Genetic Variation of Glucose-6-Phosphate Dehydrogenase: A Catalog
and Future Prospects, 67 MEDICINE 311, 311 (1988).
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individuals are normally asymptomatic. Other variants are associated
with chronic hemolytic anemia. With another type of variant, the person's
red blood cells split apart (hemolyze) on exposure to factors such as fava
beans, infections or drugs. 40
As can be readily seen, demonstrating the safety of a new medical
product can be quite complex. This complexity produces and exposes a
number of weaknesses in international cooperation. These weaknesses se-
verely inhibit the ability to use a new medical product during an interna-
tional emergency. Five general areas of weakness are discussed below.
A. Failure to Recognize Foreign Clinical Data
As complex and time consuming as these safety studies are, many of
them are repeated needlessly. National specifications for the testing of
drugs vary widely throughout the world.1 4 1 Following the Thalidomide
disaster, WHO stated that "[c]linical trials are highly time consuming,
need very large numbers of patients to be observed according to generally
accepted principals and would often be facilitated by international coop-
eration." '142 A number of countries, such as France and Mexico, requires
that scientific data used for drug approval must be produced by their own
scientists exclusively within their own borders.' 3 One of the items in-
tended for European harmonization is the regulation of pharmaceuticals
and high technology medicines.1
4 4
Some progress has been made on mutual recognition of preclinical
testing such as animal studies and methods of determining drug purity.
Agreement to Good Laboratory Practices has been reached with Japan,
the United States, the United Kingdom, Switzerland, France and West
Germany in this area. 45 These agreements stipulate that each country
will recognize preclinical data that meet the regulatory requirements of
the other nation.'4 6
Human testing is quite different. The United States accepts human
test data from other nations, provided they meet the stringent require-
ments of "adequate and well controlled studies." Provisions for their use
are made in FDA guidelines issued regarding the submission of human
clinical data.1 47 This appears to be a major exception to the international
rule.
The Japanese, for example, do not accept most U.S. clinical data.
140. Id.
141. KAY, supra note 137, at 59.
142. Id., quoting WHA 15.41 (1962).
143. KAY, supra note 137, at 60.
144. RiCHARD HURWITZ, RAF FIN. CORP. REPORT 1, 5 (1990); European Renaissance:
The Economic Implications of the 1992 Internal Market, quoting Bus. AM., August 1, 1988.
145. Fairbain, Japan: Drug Regulations - A United States Industrial Perspective, 1
REGULATORY AFF. 25, 27 (1989).
146. Id.
147. Guideline, supra note 128, at 17, 21, 23, 25, 26, 87.
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Their position is that diet and genetics can alter a drug's metabolism.
Consequently, the effects of a drug may be different in Japanese as op-
posed to other races.4 8
Certainly there are differences. Japan has a very low rate of breast
and colon cancer and a high rate of stomach cancer. In the United States,
the reverse is true. However, when Japanese immigrate to the United
States, within one or two generations, they show the high colon and
breast cancer rates and low stomach cancer typical of Americans.' 9 The
low rate of cardiovascular disease in Japan changes in Japanese-Ameri-
cans who switch to American diets.5 0 One wonders if this is true scientific
justification for requiring across-the-board duplication of American
clinical data.
B. Multinational Requirements for Animal Testing
As discussed above, some agreements on mutual recognition of
animal test data have been reached. However, as they currently stand,
these procedures have a number of serious flaws. Their inherent weak-
nesses are another impediment to the use of new medical technologies in
a crisis.
As evidenced by cigarette smoking, a twenty to thirty year period
may exist between initial exposure to a carcinogen and the appearance of
cancer.' 5' Studies on animals, particularly for the purpose of testing for
cancer or birth defects, are therefore required by most nations. Included
among these are the United States;5 2 India (2 species, 1 rat or mouse);
Sweden (2 species, 2 dose levels); the United Kingdom (2 species, 1 small
rodent or rabbit); and Venezuela (3 species, 1 a non-rodent).5 3 Animal
cancer tests cost about $250,000 and take about three years to com-
plete." Due to the many types of cancer and length of time required,
accurate detection of a product causing cancer in only one percent of the
test animals would require the use of 10,000 rats or mice. 55 Fifty animals
at each of two doses are normally used. High doses are administered to
animals in an attempt to overcome this limitation."'
The World Health Organization has considered the issue of both
animal and human testing. In 1971 and 1972, WHO urged the creation of
an International System of Information on Drugs. One of its purposes was
to "reduce repetitive animal experimentation and unnecessary exposure
148. Fairbain, supra note 145, at 29.
149. Bruce N. Ames, Identifying Environmental Chemicals Causing Mutations and
Cancer, 204 SCIENCE 587, at 587 (1979).
150. Fairbain, supra note 145, at 29.
151. Ames, supra note 149, at 587.
152. Guideline, supra note 128, at 15, 32, 42.
153. KAY, supra note 137, at 60.
154. Ames, supra note 149, at 588.
155. Id. at 589.
156. Id.
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of human subjects to drugs.91 57
More serious problems exist. In a joint Finnish and Italian study a
broad variety of chemical substances, known to cause birth defects in
humans, was surveyed for its effects on animals. " Potent chemicals, such
as PCBs, while producing malformations in mice, produced none in rats
and rabbits. Experimental effects did not consistently reproduce the
problems observed in humans, nor were they similar in different animal
species. The authors of the study noted that while some of these sub-
stances did not produce malformations, they did induce some other ef-
fects. Other effects were resorption, still birth and decreased weight gain.
As a result, they concluded that animal testing for birth defects seems
justified.1"9 However, the Advisory Subgroup in Toxicology of the Euro-
pean Medical Councils, who commissioned the study stated that:
No conclusion can be drawn on the validity of the practice of testing
chemicals for teratogenicity. The variations of doses and responses...
reinforces the view . . . that only an increase in knowledge of the
mechanism of action of embryotoxins will lead to sound methods for
the prediction of this hazard of human exposure. 6 '
In 1979, "almost all of the dozen or so organic chemicals known to
cause cancer in humans also' caused cancer in some laboratory ani-
mals."1'' Far more information is known today. The folly of over-reliance
on animal testing is further indicated by the fact that lactose, the sugar in
human breast milk, causes cancer in rats. Common table salt, in large
amounts, causes birth defects in mice. Vitamin A, used by the human
body to strengthen bone, is as toxic to rodents as the pesticide parathion.
Thalidomide, which caused birth defects in thousands of humans, does
not cause birth defects in either mice or rats. 6 2 Despite serious shortcom-
ings, animal safety testing is required by most international regulatory
agencies.
Alternate methods of safety testing are now being developed. The
ability of a chemical to mutate or cause damage to human DNA is likely
to be the major cause of cancer and birth defects. " In the 1970s, Dr.
Bruce Ames and his colleagues developed an assay for detecting mutagens
and carcinogens (the Ames test). It is based on the ability of a chemical
to produce a mutation in a defective bacterial gene (i.e. a strain of Salmo-
nella), enabling it to no longer require a previously required nutrient. The
157. KAY, supra note 137, at 61, 62, quoting WHA 24.56 and WHA 25.61.
158. K. Hemminki and P. Vineis, Extrapolation of the Evidence on Teratogenicity of
Chemicals Between Humans and Experimental Animals; Chemicals Other Than Drugs, 5
TERATOGENESIS, CARCINOGENESIS AND MUrrAGENrsls 251-318 (1985).
159. Id. at 282-83.
160. Id. at 252.
161. Ames, supra note 149, at 588.
162. Richard Lipkin, Risky Business of Assessing Danger, INSIGHT, May 23, 1988, at 8,
12.
163. Ames, supra note 149, at 587.
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chemical to be tested is mixed with a liver extract used to convert the
chemical to forms used in the body (metabolites). This mixture is then
placed on a nutrient solution that does not contain the element that the
bacteria previously required in order to live. After incubation for two
days, the number of bacterial colonies growing on the solution is re-
corded. Each of these colonies is composed of descendants of a bacteria
that has been mutated from having a defective genetic instruction to hav-
ing a normal one.""
The original validation of the test showed that about 90% of the
known cancer causing substances tested were detected, other studies have
confirmed this observation. 6 5 Some specific classes of cancer causing
chemicals did not respond to the test. New strains of test bacteria are
being developed for improving the accuracy of the assay. 6
A major Japanese food additive, furylfuramide (AF-2), which tested
negative in two animal cancer tests, was shown to cause cancer using the
Ames Test. 16 7 One hundred million Japanese were ingesting this com-
pound. Based on the Ames data, additional testing was ordered. AF-2 has
now been banned.'68
The Ames test is currently being used in over three thousand govern-
ment, industrial and academic laboratories throughout the world.' In-
ternationally required animal tests for carcinogenicity and birth defects
have severe limitations. In addition to the lack of mutual recognition by
several nations, animal testing for cancer and birth defects has been
demonstrated to be inaccurate on a number of occasions. Considering
these limitations, in an international health crisis, the value of short term
testing, similar to the Ames test, would be immeasurable.
C. Rules Prohibiting Transnational Cooperation
Rules prohibiting the exportation of new treatments are another im-
pediment to international cooperation during emergencies. The United
States Drug Export Amendments Act of 1986 (DEAA)'170 was designed to
help U.S. drug producers in their battles with foreign competition. It did
so by allowing drugs that were not yet approved in the U.S. to be shipped
to nations where they had been approved.' The Act requires that a do-
mestic manufacturer, prior to exporting the drug, must be actively seek-
164. Id. at 589.
165. Id.
166. Bruce Ames, The Detection of Environmental Mutagens and Potential Carcino-
gens, 53 CANCER 2034, at 2034-36 (May 15, 1984) [hereinafter Detection].
167. Bruce N. Ames and Lynne Haroun, Letter to the Editor, 62 MUTATION RESEARCH
393-95 (1979).
168. Id. at 394.
169. Detection, supra note 166.
170. 21 U.S.C. §382 (1988).
171. Note, The Impact of the Drug Export Amendment Act of 1986 on Foreign Tort
Victims, 21 VANDER. J. TRANSNAT'L L. 809, 810 (1988).
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ing approval of the drug in the United States.1 7 2 It also requires that the
drug be exported to one of only twenty-one nations.7 3 The country to
whom it is shipped must have already approved the product, and it must
be available for sale in that country.174 Applications must be submitted
ninety days before the proposed shipment date.17' The Secretary of
Health and Human Services has thirty days to review it.'
7
1
These provisions are in direct contrast to those of the Helsinki Ac-
cords, which seek to expand international cooperation in the development
and testing of new drugs. 7 7 Although the imposition of restrictions in the
DEAA are probably to prevent re-importation of unimproved drugs to
the United States, their inflexibility could have serious ramifications.
During a crisis, the use of new medical technologies overseas would be
prevented for an extended period of time. New medicines, developed
within the United States, could not be used to treat a new disease in the
country of origin, until it had been allowed to spread well beyond its
borders.
D. The Cost of Drug Production
Experience has demonstrated that the distribution of production
costs also inhibits international cooperation in an emergency. It has been
estimated that of every 5,000 to 7,000 new substances evaluated for drug
production, only 1,500 survive the initial screening. Of these, only thirty
survive detailed pharmacological tests and only one of those complete the
battery of tests and becomes a marketable drug.'78 On average, it takes
eight years and six to seven million dollars to take that drug through the
requirements of FDA approval. 17 9 WHO, in an attempt to provide needed
drugs for underprivileged nations, established a special program on essen-
tial drugs.'"0 A number of drug manufacturers agreed to provide these
drugs under "financially favorable conditions."''
Under emergency conditions, however, experience indicates that even
these minimal levels of cooperation may be difficult to maintain. In the
spring of 1957, when it was first learned that a new strain of influenza
had developed in Hong Kong, various scientific advisory committees
urged the production and distribution of massive amounts of appropriate
172. 21 U.S.C. §382(b)(1)(A)(i)(II) (1988).
173. 21 U.S.C. §382(b)(4)(A) (1988).
174. 21 U.S.C. §382(b)(1)(B) (1988).
175. 21 U.S.C. §382 (b)(3)(A) (1988).
176. 21 U.S.C. §382(b)(3)(C)(i) (1988).
177. Helsinki, supra note 57, §111(4).
178. Kay, supra note 137, at 22.
179. Marianne Lavelle, Lawyers for a New Drug Must Practice Patience, 10 NAT'L L.J.,
June 27, 1988, at 1, 20.
180. Action Programme on Essential Drugs, WHA 32.42, May 25, 1979, quoted in Ur-
sula Wasserman, WHO: Essential Drugs for Developing Countries, 16 J. WORLD TRADE L.
444 n.2 (1982).
181. Id. at 446.
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influenza vaccine. 2 Unfortunately, there was never enough vaccine avail-
able in the right place, at the right time to halt the spread of the virus.
Manufacturers had been asked to make large investments in a vaccine
with no assurance that the disease would spread. If it did not arrive, they
would not be able to sell what they had produced. The disease spread
quickly and producers could not keep up with the demand. After the epi-
demic subsided, tens of millions of doses remained unused.' 3
Conditions similar to a "black market" were created for the drug.
Some groups were able to bid successfully for a vaccine that others could
not afford. Large corporations were able to keep production lines going by
immunizing their workers, while the poor could not obtain protection. Re-
ports appeared in newspapers concerning the ability of a baseball club,
for example, to immunize its healthy team, while high risk populations
did not have access to the vaccine."" Market economics do not appear to
respond well during a health emergency.
E. Prior Experience of International Organizations: The Problem With
International Efforts
Current international organizations are ill-equipped to handle a fast-
breaking medical emergency. Where successful programs have been con-
ducted by international groups, they have been typified by narrowly de-
fined circumstances. Highly technological issues are ill-suited to these
groups.
The eradication of smallpox stands as a major achievement of the
World Health Organization. WHO-supported national programs helped
eradicate the disease through vaccinations from 1958 to its last outbreak
in 1977.185 WHO's Expanded Programmes on Immunization (EPI) are
currently credited with sparing about 200,000 children from becoming
paralyzed with polio. Over one million deaths from measles, neonatal tet-
anus and pertussis in developing countries are prevented through this
program.186 It has been postulated that these programs succeed because
they are inexpensive, easily understood, easy to implement and bring im-
mediate visible benefits."8 "
With more complex issues, however, the record is not quite as en-
couraging. Under pressure from developing nations, WHO attempted to
pass measures designed to assure uniformity of drugs sold internation-
ally. ' These proposals included the creation of regional test facilities,
182. SILVERSTEIN, supra note 84, at 20, 21.
183. Id. at 21.
184. Id. at 22.
185. D.A. Henderson et al., Principals and Lessons from the Smallpox Eradication
Programme, 65 BULL. WORLD HEALTH ORGANIZATION 535-37 (1987).
186. R.H. Henderson, et al., Immunizing the Children of the World: Progress and
Prospects, 66 BULL. WORLD HEALTH ORGANIZATION 535 (1988).
187. Id.
188. JOHN U. GRANGER, TECHNOLOGY AND INTERNATIONAL RELATIONS, 186-87 (1979).
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upgrading national regulatory capabilities, attempts to uniformalize man-
ufacturing controls, national certification of the quality of exported
pharmaceuticals and monitoring of adverse reactions to drugs.1 89
By 1976, WHO funding of the project had been severely cut. Two
reasons were seen as responsible. The first was that developing nations,
who originally pressed for the measures, eventually saw the program as
being irrelevant to their major needs. The second concerned the adminis-
trative, scientific and liability problems associated with reporting adverse
drug reactions."'
When handling scientific issues, international organizations have
been criticized for having serious weaknesses. A major problem is the
"one nation, one vote" rule that exists in the United Nations General
Assembly. 91 The bloc voting strength of underdeveloped nations has
dominated debates on technical assistance to less developed countries.
The selection of secretariats is not free from political influence. As a re-
sult, "sophisticated technological issues are frequently debated by politi-
cians and foreign ministry officials who have no expertise regarding them
nor any support of knowledgeable bureaucrats and private sector repre-
sentatives either at the meeting or in their national capitals.1 9 2
In'a rapidly developing international health crisis, this could be an
extreme handicap. Resource allocation and major decisions must be han-
dled by only the most well-informed individuals. The abuse of political
influence could result in chaos.
VIII. WALKING A TIGHTROPE - THE POLITICAL REALITIES OF DEALING
WITH A CRITICAL PRODUCT
Given their propensity for political influence and inability to deal
with technical issues, it is important to understand the realities that will
confront an international organization during a fast-breaking health care
emergency. The decision on when to release an experimental drug for
human use is highly charged politically and laden with difficult scientific
issues. The perils of releasing a drug too early or too late, are both severe
and numerous. Recent experiences in the United States and abroad illus-
trate the point.
In 1987, the FDA issued new regulations that permit the use and sale
of a drug that is still under investigation (compassionate use program).
These regulations permit such use provided the drug is used to treat an
immediate life-threatening disease, for which there is no alternative ther-
apy. The drug must be under investigation in an approved clinical trial,
and the sponsor of the clinical trial must be actively pursuing approval of
189. Id. at 187-88.
190. Id. at 188.
191. Id. at 189.
192. Id.
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the drug with "due diligence. 111 3 The purpose of the rule change was to
give desperately ill patients the opportunity to "decide for themselves
whether they would rather take an experimental drug or die of the dis-
ease untreated.1
94
The agency also created a "fast track" or expedited review process
for critically needed drugs. The aim of this policy is to cut down the time
required to review an application for the approval of a new drug. Alpha
interferon, mentioned in Section VI(A) of this article, was approved by
the FDA within six months of filing the new drug application. Even on a
fast track, FDA approval normally takes two years. 9 The antiviral drug
Azidothymidine (AZT), used in the treatment of AIDS, emerged from
testing in two years.1 96 As previously mentioned, most drug approvals
take an average of eight years. 9 ' The perils of this program have been
debated extensively in the press and in scientific periodicals.
A. The Perils of Approving a Drug Too Slowly
In an editorial entitled "Human Sacrifice," Wall Street Journal edi-
tors accused an FDA advisory committee of deciding to "sacrifice
thousands of American lives on an altar of pedantry."' 8 Advisory com-
mittees are composed of impartial experts assembled to "review and
make recommendations" with respect to matters pending before the
FDA. 199 Their comments are considered quite valuable but are not bind-
ing. The FDA commonly enlists the advice of such committees to obtain
unbiased reviews of the evaluation of a new drug product. 00 The "human
sacrifice" referred to in the editorial was that allegedly caused by the
committees decision not to recommend approval of tPA, previously re-
ferred to in section VI of this article.
On the day prior to the advisory committee meeting for tPA, another
Wall Street Journal editorial urged immediate approval.2 0' This article
stated that "bureaucratic progress must be measured against the real-
world costs of keeping this substance out of the nation's emergency
rooms," and emphasized that well over a thousand Americans go to their
deaths each day from heart attacks. 02 After the committee's refusal to
follow the Wall Street Journal editors' advice, still another editorial ap-
193. 21 C.F.R. §312.34 (1991).
194. G. Annas, FDA's Compassion for Desperate Drug Companies, HASTINGS CENTER
REPORT, January/February 1990, at 36, quoting S. Jay Plager, counselor to the Undersecre-
tary of Health and Human Services, NEW YORK TIMES, July 24, 1988, at Al.
195. Marciniszyn, supra note 103, at 151-52.
196. Id. at 154.
197. Lavelle, supra note 179, at 20.
198. Editorial, Human Sacrifice, WALL ST. J., June 2, 1987, at 30.
199. 21 C.F.R. §14.1 (1991).
200. Peter R. Kowley, et al., The TPA Controversy and the Drug Approval Process,
260, JAMA, Oct. 21, 1988, at 2250.
201. Editorial, The TPA Decision, WALL ST. J., May 28, 1987, at 30.
202. Id.
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peared. This one, entitled "The Flat Earth Committee," cited the clinical
trials used for the approval of another drug, streptokinase. The editors
decided that patients who received a placebo, in order to evaluate the
drug's effectiveness, "proved the drug's efficacy by going to their deaths"
and that data had come to supersede the purpose of helping sick people
get well.203
The advisory committee responded in a letter to the editor. They
pointed out that without adequate and well-controlled data, one cannot
distinguish between the wise early approval of a good drug, and the un-
wise early approval of a bad one.20 4 With regard to tPA, a higher inci-
dence of cerebral hemorrhage (bleeding in the brain) was observed at the
higher dosage levels of the drug. A severe stroke or death could occur in
one to four percent of the patients, at these higher dosage levels. The
dose of the drug was then reduced, but relatively few patients getting the
lower dose had been reported on in full. More data was needed to show
safety. In addition, the drugs used in the study were produced by two
different methods with one form differing from the other in several re-
spects. These included both the time the drugs remained in the blood-
stream and their peak effects. 20 5 The effects of the two needed greater
clarification. The additional data was produced and the drug was ap-
proved six months later.
In a separate response, the committee stated that had it recom-
mended approval, sponsors might be lead to believe that "predeliberation
pressure could force approval of an incompletely evaluated compound. '20 6
In the advisory committee meeting regarding EPO, also referred to in sec-
tion VI, an AIDS activist threatened to put thousands of AIDS activists
at the doorstep of the FDA if the drug was not approved immediately. 20 7
EPO might correct the anemia experienced by AIDS victims as a side
effect of therapy.
B. The Perils of Approving a Critical Drug Too Quickly
Through the FDA's compassionate use program, Dideoxyinosine
(DDI) was released to a greater number of patients while still under in-
vestigation. The drug is thought to be free of the side effects associated
with AIDS treatment using current drugs. A recent report from the man-
ufacturer indicated that of 8,000 patients who had been taking the drug,
290 died. While the National Health Institute observed that the death
rate was lower than that for the early trials of AZT, others labeled the
death rate "a disgrace," and called for more tightly controlled clinical
203. Editorial, The Flat Earth Committee, WALL ST. J., July 13, 1987, at 22.
204. Letters to the Editor, The FDA Cardio-Renal Committee Replies, WALL ST. J.,
Aug. 12, 1987, at 19.
205. Id.
206. Kowley, supra note 200, at 2251.
207. Meeting attended by author.
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trials.2 "
While the "compassionate use" or "expanded access" program is
fairly new and for use with critical drugs only, history contains several
horror stories of non-critical drugs brought to the market too quickly.
Clioquinol, an antidiarrhea medication, caused blindness, paralysis or
death. In Japan alone, more than 10,000 people were injured by the
drug.20 9 High dose isoprenaline, administered to asthmatics, was responsi-
ble for sudden cardiac failures in England. 210 Genital malfcrmations were
found to be caused by the drug diethylstilbestrol (DES)." Thalidomide
caused thousands of birth defects.1 2 The effects of these drugs were not
immediate.
In another case, the drug Azaribine (Triazure) was withdrawn from
the market in the United States after being sold for one year. The drug
was found to be responsible for inducing blood clots. Eight cases were
reported with one death. A congressional hearing was held to determine if
the FDA had not done enough to protect patients.21
In 1979, the United States Supreme Court considered the petition of
cancer patients denied the drug laetrile. 21 "4 The court stated that a drug is
unsafe where its potential for injury may outweigh the possibility of bene-
fit, and that the FDA has never made exception for drugs used by the
terminally ill.2 15 They also stated that Congress expressed concern that
individuals with fatal illnesses should be shielded from fraudulent
cures.
2 18
The tightrope on which regulatory agencies must walk is extremely
narrow. Political and media pressures increase greatly when considering a
drug for the treatment of a terminal illness. In these situations, no matter
what the decision, the only thing one is guaranteed is intense opposition.
It is a perpetual case of damned if you do and damned if you don't.217
Current international organizations are clearly not structured to handle
these pressures.
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IX. CONCLUSIONS AND RECOMMENDATIONS
This article began with an examination of the historical and legal de-
velopment of human rights philosophies, and their evolution into differ-
ent systems. Each system has its unique problems. These problems be-
come more severe when different philosophies and systems are forced to
work together. Such would be the case in a sudden international emer-
gency. Based on prior experience and current scientific knowledge, that
emergency is a very real possibility.
The delivery of new, safe medical products to those in need is an
important aspect of providing equal access to health care. It is ironic that
so many nations that see health care as a human right, yet refuse to ac-
cept foreign clinical test data demonstrating the effectiveness of new
products. The paradox is extended by the fact that a major nation that
does not recognize health care as a right, the United States, has been
willing to accept human test data from other nations. In the United
States, however, export laws exist that bar the overseas shipment of an
experimental drug. In the event of a rapidly breaking crisis, these barriers
must fall. International cooperation is imperative during a global medical
crisis. Until recently, animal testing was all that was available to deter-
mine the long-term side effects of drugs. A few international agreements
have been reached with regard to mutual acceptance of animal test data.
This is only part of the problem. Studies have clearly demonstrated the
pitfalls of over-reliance on animal testing. In addition to being time-con-
suming and expensive, they can be inaccurate.
New methods of testing, such as the Ames test, provide a measure of
hope for resolving these difficulties. With improvement in short-term
tests, reliance on extensive animal testing might be reduced. This could
be critical in a worldwide emergency. International cooperation and mu-
tual recognition of test methods would again be required.
Some precedent for this concept exists. Testing drugs and devices for
fever-producing substances (pyrogens) was primarily accomplished by
testing rabbit colonies for temperature elevation following injection of the
drug or an extract of a device. ' As with other animal tests, the method
was expensive, time-consuming and subject to variability.2"9 In 1973, the
FDA announced approval of a substitute that could be performed in a
test tube (the LAL test).2 ° It was found to be more accurate, faster and
less expensive than using rabbits. Guidelines on its validation for routine
use by drug and device manufacturers were issued in 1987.22 '
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219. U.S. Department of Health and Human Services Sterile Medical Devices - A
GMP Workshop Manual 432 (4th ed. 1984).
220. 38 Fed. Reg. 1404 (1973).
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Costs and methods of reimbursement likewise inhibit the use of new
medical products during an emergency. Manufacturers need some finan-
cial assurances before launching into production of a product for which a
market might not be waiting. Without such assurances, both shortages
and a black market in medicine may develop.
The resolution of each of these problems requires a high level of in-
ternational cooperation. Current international organizations are ill-
equipped to handle these issues. Political pressures associated with criti-
cal medical products are enormous. The lack of technical expertise, cou-
pled with the politics of a "one-nation, one-vote" system, renders many
current international organizations incapable of dealing effectively with
challenges of this magnitude.
A new international accord is needed to formulate a world crisis
strategy. Elements of that strategy should include the following:
1. The transnational recognition of human clinical test data, generated
in accordance with mutually defined practices, for use in an
emergency.
2. The identification of true human genetic variants and their incorpo-
ration into a worldwide system for mutually recognized clinical
testing.
3. Mutual recognition of animal test data coupled with the funding,
development and acceptance of alternatives.
4. The creation of an account, within the World Bank, for the purpose
of funding increased production of new drugs. This account could be
used by qualified manufacturers in the early stages of a potential
health crisis. By doing so, manufacturers would have some assurance
of expense reimbursement while the new drug might be provided ear-
lier to help slow the spread of the disease.
5. The appointment of a highly qualified group of independent medi-
cal experts to oversee and direct these activities. This would include
the oversight of qualified clinical investigators and the international
use of experimental substances during emergencies.
Our recent history has demonstrated that we must at least have the
capacity to respond to a worldwide medical emergency. International
proclamations regarding health for all and equal access to health care are
truly admirable and represent worthy goals. Without confronting the re-
alities that divide us, however, we are blowing an uncertain trumpet.2 2
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